ArticleBritish journal of pharmacology2001
Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells.
Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 110 citations in OpenAlex.
- IFC-305, an adenosine derivative, inhibits the osteolytic metastases of triple-negative breast cancer.Journal of bone oncology · 2025Article
- Review
- CD73: a new immune checkpoint for leukemia treatment.Frontiers in immunology · 2025Review
- Current Understanding of the Role of Adenosine Receptors in Cancer.Molecules (Basel, Switzerland) · 2024Review
- Ultrasonic-assisted synthesis and antitumor evaluation of novel variant heterocyclic compounds based on piperidine ring.Future medicinal chemistry · 2024Article
- Ultrasonic-induced synthesis of novel diverse arylidenesRSC advances · 2023Article
- Neuroprotective Roles of the Adenosine ANeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- ADORA1 is a diagnostic-related biomarker and correlated with immune infiltrates in papillary thyroid carcinoma.Journal of Cancer · 2021Article
- Pharmacological characterisation of novel adenosine AScientific reports · 2020Article
- Involvement of AJournal of molecular neuroscience : MN · 2019Article
- ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.Medical oncology (Northwood, London, England) · 2019Article
- Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.International journal of molecular sciences · 2018Review
- A binding kinetics study of human adenosine ABiochemical pharmacology · 2018Article
- AMedicinal research reviews · 2018Review
- Discovery of benzothiazolylquinoline conjugates as novel human ARoyal Society open science · 2018Article
- PreclinicalContrast media & molecular imaging · 2018Article
- Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.Frontiers in immunology · 2017Review
- Inosine Released from Dying or Dead Cells Stimulates Cell ProliferationFrontiers in immunology · 2017Article
- Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.Nature reviews. Rheumatology · 2017Review
- Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor.European journal of nuclear medicine and molecular imaging · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The present work was devoted to the study of A3 adenosine receptors in Jurkat cells, a human leukemia line. 2. The A3 subtype was found by means of RT-PCR experiments and characterized by using the new A3 adenosine receptor antagonist [3H]-MRE 3008F20, the only A3 selective radioligand currently available. Saturation experiments revealed a single high affinity binding site with K(D) of 1.9+/-0.2 nM and B(max) of 1.3+/-0.1 pmol mg(-1) of protein. 3. The pharmacological profile of [3H]-MRE 3008F20 binding on Jurkat cells was established using typical adenosine ligands which displayed a rank order of potency typical of the A3 subtype. 4. Thermodynamic data indicated that [3H]-MRE 3008F20 binding to A3 subtype in Jurkat cells was entropy- and enthalpy-driven, according with that found in cells expressing the recombinant human A3 subtype. 5. In functional assays the high affinity A3 agonists Cl-IB-MECA and IB-MECA were able to inhibit cyclic AMP accumulation and stimulate Ca(2+) release from intracellular Ca(2+) pools followed by Ca(2+) influx. 6. The presence of the other adenosine subtypes was investigated in Jurkat cells. A1 receptors were characterized using [3H]-DPCPX binding with a K(D) of 0.9+/-0.1 nM and B(max) of 42+/-3 fmol mg(-1) of protein. A2A receptors were studied with [3H]-SCH 58261 binding and revealed a K(D) of 2.5+/-0.3 nM and a B(max) of 1.4+/-0.2 pmol mg(-1) of protein. 7. In conclusion, by means of the first antagonist radioligand [3H]-MRE 3008F20 we could demonstrate the existence of functional A3 receptors on Jurkat cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.